The long and frustrating search for something--anything--that can treat Alzheimer's or blunt its symptoms ran into yet another Phase III roadblock this morning as Baxter International reported that its Phase III study of the immune-bolstering treatment Gammagard ended in failure.
There has been growing buzz among Alzheimer's researchers that they need to shift their attention to early-stage patients, whose brains are not yet severely damaged by the disease. The FDA added its voice to the move, offering a new draft guidance today aimed at shooing investigators toward a more realistic goal.
Eli Lilly's ($LLY) solanezumab has secured an endorsement from Alzheimer's researchers, who will study the experimental drug as a preventive therapy against the memory-robbing disease in patients before symptoms emerge.
Noted neurologist and Alzheimer's investigator Sid Gilman has parted ways with the University of Michigan, just days after he figured prominently in the largest insider trading case ever brought by the SEC.
In what has become a holiday tradition here at FierceBiotech , we're offering readers a look back at our most popular stories of the year. Check it out >>
Alzheimer's research has been dominated for years by the amyloid beta hypothesis: Toxic loads of the protein build up in the brain, blighting its ability to retain memories. Cut amyloid levels, say advocates, and you can delay or prevent the disease.
Johnson & Johnson is making deep cuts in an Alzheimer's immunotherapy unit in the aftermath of a colossal Phase III failure of a program to advance bapineuzumab against the memory-stealing disease, Pharmalot reported. And the company's budget ax is falling on a total of 130 jobs, hitting the hardest at an R&D operation in South San Francisco.
Drug development is a tough business. Sometimes, just when you think you're getting to the pot at the end of the rainbow, you find the trap door one step away. It's not supposed to work that...
2012 has seen some of the biggest failures in the history of drug R&D. Click here to see my top 5 flops of the year >>
The medical device company's CNS Drug Delivery chief Lisa Shafer told Bloomberg that Medtronic's approach can give pharma companies the inside track on getting their treatments through the blood-brain barrier, offering a straight shot at the beta amyloid buildup that many have targeted.